LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in … Read more
LB Pharmaceuticals Inc Common Stock (LBRX) - Net Assets
Latest net assets as of September 2025: $310.22 Million USD
Based on the latest financial reports, LB Pharmaceuticals Inc Common Stock (LBRX) has net assets worth $310.22 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($320.75 Million) and total liabilities ($10.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $310.22 Million |
| % of Total Assets | 96.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LB Pharmaceuticals Inc Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how LB Pharmaceuticals Inc Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LB Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual net assets of LB Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-94.55 Million | -174.28% |
| 2023-12-31 | $-34.47 Million | -19.65% |
| 2022-12-31 | $-28.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to LB Pharmaceuticals Inc Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6937700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Comprehensive Income | $111.00K | % |
| Other Components | $9.66 Million | % |
| Total Equity | $-94.55 Million | 100.00% |
LB Pharmaceuticals Inc Common Stock Competitors by Market Cap
The table below lists competitors of LB Pharmaceuticals Inc Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Groupe Carnivor SA
PA:MLGRC
|
$222.70K |
|
Badger Capital Corp
V:YVR-P
|
$222.80K |
|
STRATS SM Trust for Allstate Corp Securities Series 2006-3 IC
NYSE:GJT
|
$222.98K |
|
Tinybeans Group Limited
PINK:TNYYF
|
$223.12K |
|
INTERPARFUMS
STU:I8P
|
$222.52K |
|
BankInv Glob AktAnsv Udv Akk A
CO:BAIGAAUAA
|
$222.52K |
|
BROWN NON VTG-B
BE:BF5B
|
$222.27K |
|
LENZING
BE:LEN
|
$222.23K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LB Pharmaceuticals Inc Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -34,473,000 to -94,554,000, a change of -60,081,000.
- Net loss of 63,102,000 reduced equity.
- New share issuances of 40,000,000 increased equity.
- Other comprehensive income decreased equity by 163,000.
- Other factors decreased equity by 36,816,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-63.10 Million | -66.74% |
| Share Issuances | $40.00 Million | +42.3% |
| Other Comprehensive Income | $-163.00K | -0.17% |
| Other Changes | $-36.82 Million | -38.94% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares LB Pharmaceuticals Inc Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-8.14 | $24.42 | x |
| 2023-12-31 | $-9.74 | $24.42 | x |
| 2024-12-31 | $-26.71 | $24.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LB Pharmaceuticals Inc Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.83 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.65 Million |
Industry Comparison
This section compares LB Pharmaceuticals Inc Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $310.22 Million | 0.00% | 0.03x | $222.59K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |